ImmunityBio, Inc.
Health Care · Biotechnology
Structural: Only IL-15 superagonist with an FDA approval in oncology. Anktiva's NMIBC label addresses ~10k US patients/year where the alternative is radical cystectomy; commercial ramp began mid-2024 with payer access widening through 2025.
Pipeline reads (lung w/ checkpoint, pancreatic, HIV) extend the same molecule across high-unmet-need indications without new platform risk.
- Anktiva sales inflecting from launch base; gross-to-net stabilizing as Medicare/commercial coverage broadens
- Label-expansion catalysts in NSCLC (post-checkpoint failure) and lymphopenia readouts through 2026
- Soon-Shiong has personally backstopped financings, reducing acute dilution-shock risk vs typical clinical biotech
- Manufacturing in-house (Dunkirk, NY + El Segundo) - rare for a biotech this size, supports gross margin scale
- Strategic optionality: NantKwest cell-therapy assets, BioShield vaccine platform sit inside the same corporate wrapper
- Operating cash burn still materially exceeds Anktiva revenue; another raise inside 12-18 months is the base case
- Patrick Soon-Shiong control (>60%) means minority shareholders are price-takers on dilutive financings
- Going-concern language has appeared in past 10-Qs; auditor risk is non-trivial
- Float dynamics + retail concentration make $IBRX a high-beta, narrative-driven name vs cleaner biotechs like $VRTX or $REGN
No major news in the last 7 days for IBRX - only listicles and opinion pieces, which we filter out by default. See everything anyway.
No key levels recorded for this ticker.